高脂血癥是動(dòng)脈粥樣硬化的危險(xiǎn)因素，與冠心病、中風(fēng)及股動(dòng)脈狹窄等病癥息息相關(guān)，嚴(yán)重威脅人類健康。他汀類藥物因確切的療效，已成為大多數(shù)臨床醫(yī)生的首選。但大劑量服用他汀類藥物會(huì)產(chǎn)生肌毒和肝轉(zhuǎn)氨酶升高，并不適用于所有的心血管類疾病。此外貝特類和煙酸類藥物會(huì)產(chǎn)生胃腸道不適和肝腎損傷。因此尋找療效顯著、安全可靠的調(diào)血脂藥一直是醫(yī)藥工作者長(zhǎng)期研究的課題。綜述基于Pubmed上關(guān)于人高脂血癥（膽固醇、三酰甘油、LDL-C、HDL-L）主要治療藥物的相關(guān)研究，對(duì)近年來調(diào)血脂藥物研究進(jìn)展進(jìn)行綜述

Hyperlipidemia, the risk factor of atherosclerosis, closely related to the coronary heart disease, stroke, and the artery stenosis disease, is seriously threatening human health. Statins for the exact curative effects, has become the first choice to the most of the doctors in clinic. However, a large dosage of statins would cause muscle poison and associated increase in the hepatic transaminases, which is not suitable for all the cardiovascular diseases. In addition, Fibrates and niacin sequestrants would causee discomfort of gastrointestinal tract and damage of liver and kidney. Therefore, looking for the safe and reliable lipid-lowering drug with remarkable curative effect has been a project with long-term research for medicinal workers. This article reviewed the studies on new hypolipidemic drugs in recent years, which could mainly treat the hyperlipidemia (cholesterol, triglyceride, LDL-C, and HDL-L) based on the papers in the Pubmed.